Form D · Pharmaceuticals
Icagen-T, Inc.
Oro Valley, AZ · CIK 0001707449
Offering snapshot reported Sep 12, 2018 · SEC filing
- Reported sold
- $8M Offering amount: $8M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 31, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 12, 2018 | Initial | $8,000,000 | No comparison | 1 | SEC filing |
| May 25, 2017 | Initial | $8,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-321180
Source: Form D, filed Sep 12, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard Cunningham | Director, Executive |
| Mark Korb | Director, Executive |
| Douglas Krafte | Director |
| Timothy Tyson | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2090 E. Innovation Park Drive
Oro Valley, AZ, 85755
Oro Valley, AZ, 85755